Last reviewed · How we verify

NCT02605798

Comparative Open-label,Randomized, Fasting, Three Way Three Sequence Two Treatment Partial Replicate Crossover Bioequivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)

Completed Phase 1 Last updated 12 November 2015
What this trial tests

Phase 1 trial testing Elbanovir in Healthy in 24 participants. Completed in 1 October 2015.

Timeline
1 August 2015
Primary endpoint
1 September 2015
1 October 2015

Quick facts

Lead sponsorGenuine Research Center, Egypt
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Enrollment24
Start date1 August 2015
Primary completion1 September 2015
Estimated completion1 October 2015
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Genuine Research Center, Egypt — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharmaceutical industries, Egypt) versus Sovaldi 400 mg Film Coated Tablets (Gilead Sciences International Ltd. Cambridge, United Kingdom)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Genuine Research Center, Egypt trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02605798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing